About Soliqua^®

Soliqua^® is a fixed-ratio combination of two complimentary glucose lowering agents (insulin glargine and GLP1-RA lixisenatide) indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.^1,2 

Soliqua^® is available as two pens offering a wider range of dosing options with multiple starting doses for a broad range of patient needs^1,2

Complimentary MOA

Soliqua^® offers simultaneous FPG and PPG control with a complimentary mechanism of action*^1,2

FPG control
Long-acting insulin glargine (100 u/mL)^1,2

• A long-acting BI in clinical use for>15 years³
• Well characterized pharmacological effects³
• Once-daily action supported by a duration of action up to 24 h³

PPG control
Short-acting prandial GLP1-RA lixisenatide^1,2

• Reduces HbA1c without severe hypoglycemia³
• Has significant postprandial effects³
• Is associated with reductions in body weight³
• Safety established in 13 trials and ~8000 patients⁴

Footnotes
*Refer to local prescribing information for more information

Abbreviations
FPG: fasting plasma glucose; GLP1-RA: glucagon-like peptide 1 receptor agonist; MOA: Mechanism of action; PPG: post prandial glucose

OAD Uncontrolled

Ever encounter patients whose glucose levels remain uncontrolled even after multiple oral anti-diabetic medications?

LixiLan-O

Soliqua^® offers superior HbA1c reduction compared to insulin glargine (Gla-100) and GLP1-RA (lixisenatide) in insulin-naïve patients⁴

Study designs:

⁵The LixiLan-O study was an open-label, randomized, parallel-group, multinational, multicenter phase III clinical trial to investigate the efficacy and safety of iGlarLixi, a titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in 1,170 type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug. The primary efficacy end point was change in HbA1c from baseline to week 30. Changes in the following continuous secondary efficacy end points from baseline to week 30 were assessed: 2-h PPG levels during a standardized meal test, body weight, seven-point self-measured plasma glucose (SMPG) profiles, and FPG.

Footnotes
^Hypothetical patients for illustrative purposes only
^aOverall LixiLan-O data based on MMRM analysis
^bDifferences in proportion of patients achieving HbA1c <7% were analysed based on weighted average differences between treatment groups from each strata using a Cochran-Mantel-Haenszel method
*Severe symptomatic hypoglycemia defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions
†Documented symptomatic hypoglycemia defined as typical symptoms accompanied by a measured plasma glucose concentration of ≤70 mg/dl (≤3.9 mmol/l)

Abbreviations
BI: basal insulin; BMI, body mass index; CI: confidence interval; DPP4: dipeptidyl peptidase 4; FPG: fasting plasma glucose; GI: gastrointestinal; Gla 100: insulin glargine 100; GLP1-RA: glucagon-like peptide 1 receptor agonist; HbA1c: glycated hemoglobin; iGlarLixi: insulin glargine 100 + lixisenatide; LS: least square; MMRM: mixed model repeated measure; OAD: oral antidiabetic drug; PPG: post prandial glucose; SD: standard deviation; SGLT2: sodium glucose co-transporter 2